CLINICAL_TRIALS
trial_result
· 2018-04-24
Clinical Trial Update: Study of QRH-882260 Heptapeptide Application in the Colon [Phase 1]
Summary
Phase 1 study of QRH-882260 heptapeptide for colon cancer prevention has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Danielle Kim Turgeon | Conditions: Colon Cancer Prevention | Phase 1 | Status: TERMINATED